Apellis Pharmaceuticals, Inc. (APLS)

48,72 +1,08 (+2,27%) Börsenschluss: 04:00PM EDT

Apellis Pharmaceuticals, Inc.

100 Fifth Avenue
Waltham, MA 02451
United States
617 977 5700
https://www.apellis.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 702

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Cedric Francois M.D., Ph.D.	Co-Founder, President, CEO & Director	1,2M	2,36M	1972
Dr. Pascal Deschatelets Ph.D.	Co-Founder & Chief Scientific Officer	688,05k	8,37M	1970
Mr. Alec Machiels J.D., MBA	Co-Founder & Director	72,5k	N/A	1973
Mr. Timothy E. Sullivan	CFO & Treasurer	716,41k	N/A	1971
Mr. Adam J. Townsend	Chief Operating Officer	701,61k	3,2M	1978
Mr. David O. Watson Esq., J.D.	General Counsel	675,35k	N/A	1973
Mr. James G. Chopas CPA	VP, Corporate Controller & Chief Accounting Officer	N/A	N/A	1967
Ms. Meredith Kaya	Senior Vice President, Investor Relations & Strategic Finance	N/A	N/A	N/A
Ms. Karen Lewis	Chief People Officer	N/A	N/A	1973
Prof. Peter Hillmen M.D., Ph.D.	Head of Hematology Engagement & Member of PNH Scientific Advisory Board	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Corporate Governance

Apellis Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand 1. April 2024, lautet 5. Die grundlegenden Scores sind Audit: 4, Vorstand: 6, Shareholderrechte: 8, Kompensation: 4.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.